Choroid Plexus Growth: A New MS Clue for Patients

Credibility

Interest

Share:2 min read

Key Takeaway

The choroid plexus — a small brain structure that helps make cerebrospinal fluid — is larger in people with MS early in the disease and stayed larger across ages, suggesting it could be a useful, noninvasive sign of inflammation linked to certain MS genes.

What They Found

Researchers measured the choroid plexus (ChP), the tissue that makes the fluid around the brain, in healthy people and people with MS using MRI. In healthy adults the ChP size stayed about the same until age 35, then slowly grew faster with age, like how a small crack in a driveway may widen more quickly over time. People with MS had bigger ChP measurements than healthy people, even in the first year after MS started, and it grew more up to about five years before leveling off. Bigger ChP size was linked to more inflammatory lesions on MRI (areas where MS has caused damage) — think of lesions as burned spots on a lawn showing past fires. The study also found that a higher genetic risk from HLA genes (immune system genes) was tied to larger ChP, while other MS genes were not clearly linked.

Who Should Care and Why

People with MS and their caregivers should care because a larger ChP on an MRI might help track inflammation early on, similar to an early warning light on a car dashboard. Neurologists and MRI teams may use this measure to better understand a person’s level of brain inflammation without extra tests, which could influence monitoring plans. Patients newly diagnosed with MS might find this useful, since the change appears early and increases over the first few years — like a thermometer showing a fever trend. Caregivers can ask their care team whether ChP size is reported and what it might mean for treatment decisions or monitoring. This information may help guide conversations about treatment urgency, follow-up MRI timing, or enrolling in research studies that look at inflammation.

Important Considerations

This study looked at one group of people at one point in time, so it can’t prove that bigger ChP causes worse MS or predict how any one person will do over time. The measurement comes from MRI scans and special software; different machines or methods might give slightly different numbers, so results may vary between hospitals. While the study found a link to specific immune genes (HLA), genetics is only one piece of MS risk and doesn’t mean ChP size alone determines outcome or treatment needs.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Progression MS Genetics MS Diagnostics

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Neurology(R) neuroimmunology & neuroinflammation often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News